Another clinically relevant and frequently mutated gene in breast cancer is ESR1. Notably, nonsynonymous ESR1 mutations affecting the ligand-binding domain of ER generally cause a constitutive activation of ER, which results in enhanced cell proliferation and resistance to endocrine therapy in ER-positive breast cancer [77,78]. This evidence concerns the gene ESR1 and breast cancer.